TNFRSF8 and Hodgkins lymphoma: Intravenous brentuximab vedotin has proven effective as consolidation therapy after autologous stem cell transplantation (ASCT) and salvage therapy in CD30-positive classical Hodgkin lymphoma (HL) cases.